Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.

PLoS One · 2018 · PMC5786316 · PMID 29373602

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Apixaban patients had a nonsignificant trend toward a lower risk of hemorrhagic stroke (HR: 0.77, 95% CI: 0.53–1.13) compared with warfarin patients ( Fig 2B ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.